166 related articles for article (PubMed ID: 30342911)
1. Brentuximab vedotin for frontline Hodgkin lymphoma: How much will a successful trial cost patients and payers?
Shanbhag S; Prasad V
Eur J Cancer; 2018 Nov; 104():252-253. PubMed ID: 30342911
[No Abstract] [Full Text] [Related]
2. Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.
Chen R; Palmer JM; Martin P; Tsai N; Kim Y; Chen BT; Popplewell L; Siddiqi T; Thomas SH; Mott M; Sahebi F; Armenian S; Leonard J; Nademanee A; Forman SJ
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2136-2140. PubMed ID: 26211987
[TBL] [Abstract][Full Text] [Related]
3. A safety evaluation of brentuximab vedotin for the treatment of Hodgkin lymphoma.
Oak E; Bartlett NL
Expert Opin Drug Saf; 2016 Jun; 15(6):875-82. PubMed ID: 27139729
[TBL] [Abstract][Full Text] [Related]
4. Brentuximab vedotin-based salvage treatment in Hodgkin's lymphoma.
Vitolo U; Chiappella A
Lancet Oncol; 2018 Sep; 19(9):1144-1146. PubMed ID: 30122617
[No Abstract] [Full Text] [Related]
5. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
Moskowitz CH; Nademanee A; Masszi T; Agura E; Holowiecki J; Abidi MH; Chen AI; Stiff P; Gianni AM; Carella A; Osmanov D; Bachanova V; Sweetenham J; Sureda A; Huebner D; Sievers EL; Chi A; Larsen EK; Hunder NN; Walewski J;
Lancet; 2015 May; 385(9980):1853-62. PubMed ID: 25796459
[TBL] [Abstract][Full Text] [Related]
6. Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma.
Scott LJ
Drugs; 2017 Mar; 77(4):435-445. PubMed ID: 28190142
[TBL] [Abstract][Full Text] [Related]
7. Comment on "Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study.".
Picardi M; Giordano C
Haematologica; 2021 Apr; 106(4):1226-1227. PubMed ID: 33792226
[No Abstract] [Full Text] [Related]
8. Getting to transplant in Hodgkin lymphoma: BVB.
Gordon LI
Blood; 2018 Jul; 132(1):1-3. PubMed ID: 29976776
[No Abstract] [Full Text] [Related]
9. Brentuximab vedotin compared with other therapies in relapsed/refractory Hodgkin lymphoma post autologous stem cell transplant: median overall survival meta-analysis.
Bonthapally V; Yang H; Ayyagari R; Tan RD; Cai S; Wu E; Gautam A; Chi A; Huebner D
Curr Med Res Opin; 2015; 31(7):1377-89. PubMed ID: 25950500
[TBL] [Abstract][Full Text] [Related]
10. A 73% Price Reduction Does Not Indisputably Justify Routine Application of Brentuximab Vedotin as First-Line Treatment of Hodgkin Lymphoma.
Adams HJA; Kwee TC
J Clin Oncol; 2019 Apr; 37(10):852-853. PubMed ID: 30742560
[No Abstract] [Full Text] [Related]
11. Pharmacokinetics, immunogenicity, and safety of weekly dosing of brentuximab vedotin in pediatric patients with Hodgkin lymphoma.
Flerlage JE; Metzger ML; Wu J; Panetta JC
Cancer Chemother Pharmacol; 2016 Dec; 78(6):1217-1223. PubMed ID: 27837256
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage III or IV classical Hodgkin lymphoma.
Delea TE; Sharma A; Grossman A; Eichten C; Fenton K; Josephson N; Richhariya A; Moskowitz AJ
J Med Econ; 2019 Feb; 22(2):117-130. PubMed ID: 30375910
[TBL] [Abstract][Full Text] [Related]
13. [Brentuximab vedotin treatment in patients with relapsed or refractory Hodgkin lymphoma. A Hungarian retrospective study].
Molnár Z; Pinczés LI; Piukovics K; Istenes I; Wolf K; Csukly Z; Szomor Á; Illés Á; Miltényi Z
Orv Hetil; 2017 Oct; 158(41):1630-1634. PubMed ID: 29025292
[TBL] [Abstract][Full Text] [Related]
14. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical data.
Bonthapally V; Wu E; Macalalad A; Yang H; Shonukan O; Liu Y; Chi A; Huebner D
Curr Med Res Opin; 2015 May; 31(5):993-1001. PubMed ID: 25772232
[TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr virus-positive diffuse large B-cell lymphoma after frontline brentuximab vedotin treatment of classical Hodgkin lymphoma.
Tse E; Au-Yeung R; Chau D; Hwang YY; Loong F; Kwong YL
Ann Hematol; 2022 May; 101(5):1149-1152. PubMed ID: 34757467
[No Abstract] [Full Text] [Related]
16. Brentuximab vedotin: its role in the treatment of anaplastic large cell and Hodgkin's lymphoma.
Haddley K
Drugs Today (Barc); 2012 Apr; 48(4):259-70. PubMed ID: 22536568
[TBL] [Abstract][Full Text] [Related]
17. New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.
Merli M; Ferrario A; Maffioli M; Olivares C; Stasia A; Arcaini L; Passamonti F
Expert Rev Hematol; 2016 Aug; 9(8):767-80. PubMed ID: 27416486
[TBL] [Abstract][Full Text] [Related]
18. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
[TBL] [Abstract][Full Text] [Related]
19. Salvage regimens for Hodgkin's lymphoma in the brentuximab vedotin era.
Vitolo U; Chiappella A
Lancet Oncol; 2018 Feb; 19(2):162-163. PubMed ID: 29276023
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
